Compare HCKT & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCKT | LCTX |
|---|---|---|
| Founded | 1991 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.1M | 301.7M |
| IPO Year | 1998 | 1996 |
| Metric | HCKT | LCTX |
|---|---|---|
| Price | $11.16 | $1.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $17.00 | $6.25 |
| AVG Volume (30 Days) | 387.2K | ★ 932.4K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $285,862,000.00 | $14,556,000.00 |
| Revenue This Year | $2.55 | $109.40 |
| Revenue Next Year | $5.07 | N/A |
| P/E Ratio | $32.82 | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $9.16 | $1.00 |
| 52 Week High | $21.33 | $2.09 |
| Indicator | HCKT | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.03 | 39.65 |
| Support Level | $9.61 | $1.00 |
| Resistance Level | $11.89 | $1.18 |
| Average True Range (ATR) | 0.59 | 0.06 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 71.00 | 36.11 |
The Hackett Group Inc is an IP platform-based Generative Artificial Intelligence (Gen AI) strategic consulting and executive advisory digital transformation firm. The Hackett Group provides dedicated expertise in Gen AI-enabled enterprise transformation services across the front, mid and back office areas, including its highly recognized Oracle, SAP, OneStream and Coupa implementation offerings. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.